With a modest after-hours selloff, we believe long-term investors have a good entry point for a high-quality holding.

BIOPROCESSING OPERATIONS RECORDS 3 CONSECUTIVE QUARTERS OF REVENUE GROWTH OPERATIONAL EFFICIENCIES CUT QUARTER AND YTD NET LOSSES BY 46% AND 34% TWO MAJOR NEW PRODUCTS TO LAUNCH IN Q1 2025 Investor Ca ...